Hsa_circ_0032131 knockdown inhibits osteoarthritis progression via the miR-502-5p/PRDX3 axis

被引:13
|
作者
Xu, Jin [1 ]
Ma, Xinlong [1 ]
机构
[1] Tianjin Hosp, Dept Pain Treatment, Tianjin 300211, Peoples R China
来源
AGING-US | 2021年 / 13卷 / 11期
关键词
circRNA; OA; NF-KAPPA-B; MATRIX DEGRADATION; II COLLAGEN; CHONDROCYTES; APOPTOSIS; CARTILAGE; INFLAMMATION; EXPRESSION; AGGRECAN; SPONGE;
D O I
10.18632/aging.203073
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Osteoarthritis (OA) is a chronic disease characterized by progressive loss of cartilage and failure of the diarthrodial joint. Circular RNAs (circRNAs) are known to participate in the pathogenesis of multiple diseases, including OA. We investigated the functions of hsa_circ_0032131, a circRNA upregulated in OA, using CHON-001 cells and an in vivo OA rat model. CHON-001 cells were treated with interleukin (IL) -113 to mimic OA in vitro. IL 113 -induced inhibition of CHON-001 growth was reversed by silencing hsa_circ_0032131. In addition, hsa_circ_0032131 knockdown reversed IL-113 -induced activation of Trx1, Cyclin D and PRDX3, whereas overexpression of PRDX3, a direct target of miR-502-5p, reversed this effect. Hsa_circ_0032131 served as a competing endogenous RNA for miR-502-5p. Moreover, knockdown of hsa_circ_0032131 attenuated OA symptoms in vivo by inactivating the STAT3 signaling pathway. Thus, silencing of hsa_circ_0032131 inhibited the progression of OA by inactivating the miR-502-5p/PRDX3/Trx1/STAT3 axis, which highlights its potential as a therapeutic target for OA.
引用
收藏
页码:15100 / 15113
页数:14
相关论文
共 50 条
  • [31] CircRNA hsa_circ_0004771 promotes esophageal squamous cell cancer progression via miR-339-5p/CDC25A axis
    Huang, Enmin
    Fu, Junhui
    Yu, Qiuyan
    Xie, Peixin
    Yang, Zhongxian
    Ji, Huanlin
    Wang, Li
    Luo, Ganfeng
    Zhang, Yanting
    Li, Ke
    EPIGENOMICS, 2020, 12 (07) : 587 - 603
  • [32] Circular RNA hsa_circ_0061395 accelerates hepatocellular carcinoma progression via regulation of the miR-877-5p/PIK3R3 axis
    Yu, Yanhui
    Bian, Lijuan
    Liu, Renfei
    Wang, Yitong
    Xiao, Xia
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [33] Circular RNA SOX5 promotes the proliferation and inhibits the apoptosis of the hepatocellular carcinoma cells by targeting miR-502-5p/synoviolin 1 axis
    Cai, Yu
    Jia, Yuanyuan
    BIOENGINEERED, 2022, 13 (02) : 3362 - 3370
  • [34] hsa_circ_0058357 acts as a ceRNA to promote non-small cell lung cancer progression via the hsa-miR-24-3p/AVL9 axis
    Wei, Dongshan
    Sun, Lifang
    Feng, Wei
    MOLECULAR MEDICINE REPORTS, 2021, 23 (06)
  • [35] Down-regulated HSA_circ_0003528 inhibits hepatocellular carcinoma aggressiveness via the miR-212-3p/XIAP axis
    Liu, Qi
    Xu, Xin
    Sun, Wei
    BIOENGINEERED, 2022, 13 (04) : 11269 - 11280
  • [36] Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1 axis
    Zhang, Min
    Sun, Yu
    Xu, Hanzi
    Shi, Yaqian
    Shen, Rong
    Teng, Fang
    Xu, Juan
    Jia, Xuemei
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2023, 55 (04) : 574 - 586
  • [37] Knockdown of hsa_circ_0023028 inhibits cell proliferation, migration, and invasion in laryngeal cancer by sponging miR-194-5p
    Chen, Xiaofeng
    Su, Xiaoqing
    Zhu, Chuansai
    Zhou, Jing
    BIOSCIENCE REPORTS, 2019, 39
  • [38] Circular RNA hsa_circ_0008285 inhibits colorectal cancer cell proliferation and migration via the miR-382-5p/PTEN axis
    Wang, Jianjun
    Luo, Juanjuan
    Liu, Gan
    Li, Xiaomin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (02) : 503 - 510
  • [39] Hsa_circ_0101050 accelerates the progression of Colon cancer by targeting the miR-140-3 p/MELK axis
    Cheng, Kuoju
    Chen, Hao
    Chen, Bin
    Li, Jing
    Fan, Caibo
    Yan, Huan
    Huang, Wei
    Zhao, Ting
    Luo, Yun
    Peng, Lei
    TRANSLATIONAL ONCOLOGY, 2024, 44
  • [40] Knockdown of lncRNA HOTTIP Inhibits Retinoblastoma Progression by Modulating the miR-101-3p/STC1 Axis
    Yuan, XiangWen
    Sun, Zhaoyan
    Cui, Congxian
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20